flâneur

First African-made mRNA vaccine, a test platform for the future

nature.com · 781 words · saved by 1 readers

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our privacy policy for more information on the use of your personal data. Manage preferences for further information and to change your choices. Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement You can also search for this author in PubMed

Email Bluesky Facebook LinkedIn Reddit Whatsapp X You have full access to this article via your institution. Kittir Mission: Adhanom Ghebreyesus, Director-General (WHO), Petro Terblanche, managing director Afrigen Biologics and Belgium Minister for Development Cooperation Meryame Kitir during a visit to Afrigen Formulation Facilities. Credit: Benoit Doppagne/BELGA MAG/AFP via Getty Images Lire en Francais Africa has been at the back of the queue for COVID-19 vaccines compared to much of the rest of the world, largely because most of the vaccines are made by Western manufacturers. A small biote

related reading